MajorDirect oral anticoagulants (factor Xa inhibitors)×Antituberculous antibiotic
Updated · Methodology
Mechanism
Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Rifampicin strongly induces drug-metabolising enzymes and transporters, including P-gp (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA; rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin given with edoxaban lowered the mean edoxaban area under the concentration–time curve (AUC) and shortened its half-life. The effect of edoxaban may weaken (edoxaban SmPC, EMA). In the European Heart Rhythm Association table, edoxaban AUC with rifampicin is 35% lower, while its active metabolites rise to compensate (EHRA 2021). Rifampicin itself can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin SmPC, AEMPS).
Symptoms
The main risk is weaker protection against clots. In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. Bleeding is possible as well. Rifampicin can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban itself increases the risk of bleeding, including severe and life-threatening bleeding (edoxaban SmPC, European Medicines Agency, EMA).
Management
Avoid combining edoxaban with rifampicin (edoxaban label, US Food and Drug Administration, FDA). The European edoxaban summary of product characteristics (SmPC) lists rifampicin among the P-glycoprotein (P-gp) inducers that call for caution with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The dosing section of the edoxaban SmPC lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of rifampicin, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). Stopping an oral anticoagulant early without adequate replacement increases the risk of ischaemic events (edoxaban label, FDA). Rifampicin also lowers exposure to other oral anticoagulants, such as warfarin (rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin can cause vitamin K-dependent coagulopathy, so monitor for it in patients at particular risk of bleeding. Consider vitamin K supplementation in vitamin K deficiency and hypoprothrombinaemia (rifampicin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Rifaldin 300 mg cápsulas (rifampicina) (2026)– AEMPS, CIMA, nº registro 46029, secciones 4.3 y 4.5
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Rifampicina, Rifaldin 300 mg (nº registro 46029), sección 4.4 (2026)– AEMPS, CIMA, nº registro 46029 (Rifaldin 300 mg cápsulas, Sanofi Aventis), revisión 04/2026 (texto revisado 03/2026), secciones 4.4 y 4.8
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2